Author

Neil Portman

Garvan Institute of Medical ResearchORCID 0000-0003-0248-0258Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Catherine Elizabeth CaldoniD· 3 shared Elgene LimiD· 3 shared Clare StirzakeriD· 2 shared Elyssa M. CampbelliD· 2 shared Heloisa Helena MilioliiD· 2 shared Joanna Achinger-KaweckaiD· 2 shared Kee-Ming Chia· 2 shared Qian DuiD· 2 shared

Activity by Year

2021-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMolecular Biology

Catherine Elizabeth CaldonORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJan 8, 2025

JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

Sarah Alexandrou, Christine S Lee, Kristine J. Fernandez…·Catherine Elizabeth Caldon

This study identifies JNK pathway suppression as a driver of resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, with implications for patient stratification.

DOI 10.1101/2025.01.08.631992

humangenetic perturbation / CRISPR

𝕏 PostBluesky

Molecular BiologyNature Structural & Molecular BiologyPeer-reviewedJan 5, 2024

Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer

Joanna Achinger-Kawecka, Clare Stirzaker, Neil Portman…·Susan J. Clark

This study shows that Decitabine suppresses tumour growth in ER+ breast cancer by inducing DNA hypomethylation and altering 3D chromatin structure.

41 citationstop 3%

mouseDNA methylation

𝕏 PostBluesky

Molecular BiologyCell ReportsPeer-reviewedSep 1, 2021

DNA methylation is required to maintain DNA replication timing precision and 3D genome integrity

Qian Du, Grady C. Smith, Phuc‐Loi Luu…·Susan J. Clark

This study shows DNA hypomethylation disrupts replication timing precision and 3D genome organisation in colorectal cancer DNMT1 and DNMT3B knockout cells.

65 citationstop 5%

mouseHi-C

𝕏 PostBluesky